DRKS00017724
Completed
未知
Metastatic Melanoma Patients Under Immunotherapy: Monitoring of Therapeutic Success Using Liquid Biopsy and PET/CT in a Prospective Study - MM_PET/CT+LB
niversitäts-Hautklinik Tübingen0 sites100 target enrollmentAugust 1, 2019
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- C43
- Sponsor
- niversitäts-Hautklinik Tübingen
- Enrollment
- 100
- Status
- Completed
- Last Updated
- last year
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •unresectable malignant melanoma stage IV
- •Age \=18 years
- •Indicated dual immunotherapy with nivolumab and ipilimumab
- •PET/CT examinations for clinical indication before treatment initiation (baseline staging) and for therapy control (3\-monthly)
- •at least one existing measurable lesion
Exclusion Criteria
- •non\-consenting patients
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Phase 2
Efficacy of immunotherapy in melanoma patients with brain metastases treated with steroids. The MEMBRAINS trial2024-516585-11-00Region Hovedstaden50
Active, not recruiting
Phase 1
Treatment of skin cancer using a different approach than surgery using an electroporation device that makes the tumour absorb more drug while leaving the healthy tissue alone combined with an immune modulator that enhances the anti-tumour immune response.Advanced Melanoma CancerTherapeutic area: Diseases [C] - Cancer [C04]EUCTR2014-004420-22-IEniversity College Cork10
Active, not recruiting
Phase 1
Immunization of disease-free melanoma patients with different HLA-A2 peptides.We want to vaccine HLA-A2 patients who had a cutaneous melanoma at the following AJCC stage T3b-T4 N0 M0, Tx N1-3 M0, Tx Nx M0. Disease-free after surgery. With no previous immunizations with the same peptides is allowed if a CTL response was observed. And the patients must be met all the inclusion criteria.EUCTR2006-000228-14-BECliniques Universitaires Saint-Luc28
Active, not recruiting
Not Applicable
Treatment of patients with metastatic melanoma with TadalafilPreviously treated metastatic melanoma in stage IV or III unresectableMedDRA version: 14.0Level: LLTClassification code 10027481Term: Metastatic melanomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2011-003273-28-DERuprecht-Karls-University Heidelberg, Med Faculty represented by Universitätsklinikum Heidelberg and its Commercial D12
Not yet recruiting
Phase 2
Treatment of patients with metastatic melanoma (AJCC stage IV or III unresectable) with the PDE-inhibitor Tadalafil:A Pilot Trial for Proof of Principle”DRKS00003495niversitätsklinikum Heidelberg12